The Life Sciences team advised Royalty Pharma on its agreement to purchase tiered, sales-based royalty rights on the future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) for $100 million. Royalty Pharma has also agreed to purchase $50 million in common shares of Biohaven.
Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators.
For additional details on the transactions, please read the press release.